Contineum Therapeutics (CTNM) Operating Leases (2023 - 2026)

Contineum Therapeutics' Operating Leases history runs 4 years deep, the most recent figure standing at $4.7 million for Q1 2026.

• On a quarterly basis, Operating Leases rose 2.29% year-over-year to $4.7 million in Q1 2026; TTM through Mar 2026 was $4.7 million, a 2.29% increase from a year earlier, with the FY2025 full-year figure at $5.9 million, down 5.59% from the prior year.
• Operating Leases declined to $4.7 million in Q1 2026 per CTNM's latest filing, from $5.9 million in the prior quarter.
• Across five years, Operating Leases topped out at $6.3 million in Q4 2024 and bottomed at $108000.0 in Q4 2023.
• The 4-year median for Operating Leases is $4.3 million (2025), against an average of $3.3 million.
• Across the five-year window, Operating Leases surged 5695.37% in 2024 and decreased 5.59% in 2025, its largest moves.
• Year by year, Operating Leases stood at $108000.0 in 2023, then jumped by 5695.37% to $6.3 million in 2024, then fell by 5.59% to $5.9 million in 2025, then dropped by 21.29% to $4.7 million in 2026.
• Per Business Quant, the three latest CTNM Operating Leases figures stand at $4.7 million (Q1 2026), $5.9 million (Q4 2025), and $4.0 million (Q3 2025).